ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Stock Price Cross Above 200-Day Moving Average – Here’s Why

Posted by Defense World Staff on Nov 26th, 2024

Shares of ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS – Get Free Report) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $15.85 and traded as high as $16.24. ProShares UltraShort Nasdaq Biotechnology shares last traded at $16.18, with a volume of 17,471 shares trading hands.

ProShares UltraShort Nasdaq Biotechnology Stock Down 2.9 %

The business has a 50 day moving average price of $15.47 and a 200 day moving average price of $15.84.

ProShares UltraShort Nasdaq Biotechnology Cuts Dividend

The company also recently disclosed a dividend, which was paid on Wednesday, October 2nd. Stockholders of record on Wednesday, September 25th were paid a dividend of $0.1518 per share. The ex-dividend date was Wednesday, September 25th.

Institutional Investors Weigh In On ProShares UltraShort Nasdaq Biotechnology

An institutional investor recently bought a new position in ProShares UltraShort Nasdaq Biotechnology stock. Jane Street Group LLC purchased a new position in ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS – Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 10,520 shares of the company’s stock, valued at approximately $158,000. Jane Street Group LLC owned 4.78% of ProShares UltraShort Nasdaq Biotechnology at the end of the most recent quarter.

About ProShares UltraShort Nasdaq Biotechnology

(Get Free Report)

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.